GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » Cash Ratio

Wuhan YZY Biopharma Co (HKSE:02496) Cash Ratio : 1.13 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Wuhan YZY Biopharma Co Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Wuhan YZY Biopharma Co's Cash Ratio for the quarter that ended in Dec. 2023 was 1.13.

Wuhan YZY Biopharma Co has a Cash Ratio of 1.13. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Wuhan YZY Biopharma Co's Cash Ratio or its related term are showing as below:

HKSE:02496' s Cash Ratio Range Over the Past 10 Years
Min: 1.13   Med: 1.36   Max: 1.8
Current: 1.13

During the past 3 years, Wuhan YZY Biopharma Co's highest Cash Ratio was 1.80. The lowest was 1.13. And the median was 1.36.

HKSE:02496's Cash Ratio is ranked worse than
70.09% of 1508 companies
in the Biotechnology industry
Industry Median: 2.955 vs HKSE:02496: 1.13

Wuhan YZY Biopharma Co Cash Ratio Historical Data

The historical data trend for Wuhan YZY Biopharma Co's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan YZY Biopharma Co Cash Ratio Chart

Wuhan YZY Biopharma Co Annual Data
Trend Dec21 Dec22 Dec23
Cash Ratio
1.80 1.36 1.13

Wuhan YZY Biopharma Co Semi-Annual Data
Dec21 Dec22 Dec23
Cash Ratio 1.80 1.36 1.13

Competitive Comparison of Wuhan YZY Biopharma Co's Cash Ratio

For the Biotechnology subindustry, Wuhan YZY Biopharma Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan YZY Biopharma Co's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Wuhan YZY Biopharma Co's Cash Ratio falls into.



Wuhan YZY Biopharma Co Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Wuhan YZY Biopharma Co's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=215.129/190.121
=1.13

Wuhan YZY Biopharma Co's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=215.129/190.121
=1.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuhan YZY Biopharma Co  (HKSE:02496) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Wuhan YZY Biopharma Co Cash Ratio Related Terms

Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan YZY Biopharma Co (HKSE:02496) Business Description

Traded in Other Exchanges
N/A
Address
No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Hubei Province, Wuhan, CHN
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing new class of innovative medicines in respect to anti-tumor bispecific antibody.
Executives
Dragon Merit Holdings Limited 2201 Interest of corporation controlled by you
Robust Sun Holdings Limited 2201 Interest of corporation controlled by you
Cspc Pharmaceutical Group Limited 2201 Interest of corporation controlled by you
Shi Yao Ji Tuan En Bi Pu Yao Ye You Xian Gong Si 2101 Beneficial owner
He Bei Yi Er Qi Ye Guan Li Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Mei Shan Bao Shui Gang Qu Guang Rui Hong Xiang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Guo Xin Si Chuang Tou Zi Ji Jin Guan Li Bei Jing You Xian Gong Si 2201 Interest of corporation controlled by you
Guo Hong Wei
Nan Jing Cai Zhi Er Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Nan Ning Hui You Xing Yao Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Nan Ning Yao You Shang Wu Zi Xun He Huo Qi Ye You Xian He Huo
Wen Zhi Cheng
Tong De Qian Yuan Bei Jing Tou Zi Guan Li You Xian Gong Si
Wang Hongjie 2201 Interest of corporation controlled by you
Wu Shangzhi 2201 Interest of corporation controlled by you

Wuhan YZY Biopharma Co (HKSE:02496) Headlines

No Headlines